Literature DB >> 6147948

Dopamine-beta-hydroxylase and acetylcholinesterase activities of cerebrospinal fluid in Alzheimer's disease.

H Soininen, A Pitkänen, T Halonen, P J Riekkinen.   

Abstract

Recent neurochemical studies have indicated that in Alzheimer's disease there is disturbance of the cholinergic metabolism of the brain. Defects in other transmitter systems have also been suggested. As a marker of noradrenergic metabolism of the central nervous system, we measured dopamine-beta-hydroxylase (EC. 1.14.17.1) activity in cerebrospinal fluid (CSF) from 60 Alzheimer patients and 20 controls of the same age and sex. Dopamine-beta-hydroxylase activities of the CSF from Alzheimer patients did not differ significantly from those for the controls. The dopamine-beta-hydroxylase activities were not correlated with severity of dementia. As reported previously, the activity of a cholinergic marker, acetylcholinesterase (EC 3.1.1.7), was reduced in the CSF of Alzheimer patients. Interestingly, dopamine-beta-hydroxylase activities were correlated with acetylcholinesterase activities both in Alzheimer patients and control group.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147948     DOI: 10.1111/j.1600-0404.1984.tb00799.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.

Authors:  P Hartikainen; H Soininen; K J Reinikainen; J Sirviö; R Soikkeli; P J Riekkinen
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  A long-term follow-up study of cerebrospinal fluid acetylcholinesterase in delirium.

Authors:  H J Koponen; J Sirviö; U Lepola; E Leinonen; P J Riekkinen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

3.  Acetylcholine synthesis in human CSF: implications for study of central cholinergic metabolism.

Authors:  S T DeKosky; S W Scheff; C G Hackney
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.